[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mayer-rokitansky-kuster-hauser-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mayer-rokitansky-kuster-hauser-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,76,98,123,148],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100459473","uterine-transplant-for-women-with-absolute-uterine-factor-infertility-aufi-100459473",false,"NCT05263076","Uterine Transplant for Women With Absolute Uterine Factor Infertility (AUFI)","Uterine Transplantation and Pregnancy Induction in Women Affected by Absolute Uterine Factor Infertility","RECIPIENT INCLUSION CRITERIA\n\n1. Women who are diagnosed with Absolute Uterine Factor Infertility (AUFI) and who have at least one functioning ovary.\n2. Women of childbearing age (20-40 years old) who are biologically female (XX karyotype).\n3. Subjects will not have active human 142 papillomavirus (HPV) or active cervical dysplasia present.\n4. Subjects will have negative testing for Gonorrhea Chlamydia and Syphilis and will not have any active bacterial vaginosis or candida infection. (Subjects with previously treated STDs will be included if the infection is no longer present and has no impact. If a subject develops an STD\u002Finfection pre-operatively, she will be treated and monitored for a period of 3 months until she is no longer affected. She will then become eligible for transplant. If a subject develops an STD\u002Finfection after transplant\u002Fduring pregnancy she will be treated appropriately. Prior to the embryo transfer the patient will be tested and treated if necessary. Any patient with an active STD\u002Finfection will be ineligible for any elective procedure until she is tested and treated appropriately.)\n5. Subjects who are HSV-2 negative or who have a history of HSV-2 with no current symptoms. Subjects may require preventative maintenance per study doctor discretion.\n6. Subjects have received counseling regarding all fertility options and alternatives to uterine transplant such as adoption or surrogate pregnancy.\n7. Subjects are willing to undergo in-vitro fertilization to obtain the necessary 4 viable embryos required for eligibility for transplant if they have not already banked 4 viable embryos.\n8. Subjects have been evaluated by a fertility specialist and determined to have good ovarian reserve and reproductive potential.\n9. Subjects must agree that in the event of withdrawal from the study while the transplanted uterus is in place, unless she is enrolled in an equivalent uterine transplant program, she will be required to undergo a hysterectomy for her own safety.\n10. Subject meets psychological recipient criteria.\n11. Subject must be willing to complete questionnaires about their infant's growth and development and return them to the study team.\n\nRECIPIENT EXCLUSION CRITERIA\n\n1. Subject with Diabetes Mellitus Type I and II by medical history or elevated hemoglobin A1c blood test.\n2. Subject has known hypersensitivity to Tacrolimus, Thymoglobulin or Everolimus.\n3. Subject with a diagnosis of hypertension, or any other significant medical condition that makes this procedure unsafe or is a contraindication to surgery or anesthesia.\n4. Subject who has a history of solid organ or bone marrow transplant, per investigator's discretion.\n5. Subject who has a history of cancer, per investigator's discretion.\n6. Subject with a body mass index \\>30.\n7. Subject with an active infection including candida and\u002For bacterial vaginosis.\n8. Subject who is seropositive for HIV, HBV, HCV.\n9. Subject with technical obstacles as per anatomical malformations, which pose a high surgical risk in the judgment of the investigator.\n10. Subject unwilling or unable to comply with study requirements.\n11. Subject unable to undergo in-vitro fertilization or not cleared for transplant.\n12. Subject who has smoked within the last 6 months.\n13. Subject who has alcohol or drug abuse within 12 months of screening.\n14. Subject with any pre-existing clinical or medical conditions that would put the subject at an increased risk. Of note, for Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome, the investigators will favor Type 1 variants as Type 2 is associated with skeletal\u002Fspinal and renal anomalies, making them higher risk candidates.\n\nDONOR INCLUSION CRITERIA\n\n1. Women must be between 25-65 years of age. If a subject is less than 40 years old she must be certain that she does not wish to carry more children, and she will attest to this decision.\n2. Subjects will not have active human 142 papillomavirus (HPV) or active cervical dysplasia present.\n3. Subjects will have negative testing for Gonorrhea, Chlamydia and Syphilis and will not have any active bacterial vaginosis or candida infection. (Subjects with previously treated STDs will be included if the infection is no longer present and has no impact. If a subject develops an STD\u002Finfection pre-operatively, she will be treated and monitored for a period of 3 months until she is no longer affected. Any patient with an active STD\u002Finfection will be ineligible for any elective procedure until she is tested and treated appropriately.)\n4. Subjects who are HSV-2 negative, or have a history of HSV-2 but with no current symptoms. Subjects may require preventative maintenance per study doctor discretion.\n5. Subjects will have a normal uterus on sonogram and CT.\n6. Subjects will have normal psychological donor criteria (if living).\n7. Subjects will have had at least one prior full term live birth.\n\nDONOR EXCLUSION CRITERIA\n\n1. Donor over the age of 65.\n2. Body mass index \\>30.\n3. Subject with an active infection including candida and\u002For bacterial vaginosis.\n4. Subject who is seropositive for HIV, HBV, HCV\n5. Subject who has had cancer in the last five years.\n6. Subject with any pre-existing clinical or medical condition that would place the subject at an increased risk or would be a contraindication to surgery or anesthesia.\n7. Subject who has smoked within the last 6 months.\n8. Subject who has alcohol or drug abuse within 12 months of screening.\n9. Subject unwilling or unable to comply with study requirements.","FEMALE","20 Years","65 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","Absolute Uterine Factor Infertility (AUFI) is due to congenital or surgical absence of a uterus or the presence of a nonfunctional uterus. Until 2014, the only option for women affected by Absolute Uterine Factor Infertility (AUFI) was adoption or surrogate motherhood. Uterine transplant is a new form of transplant to treat AUFI. The technique of uterus transplant was developed in Sweden with the transplantation of the uterus from a living donor to a woman affected by AUFI. Approximately 80 uterine transplantations have been performed, more than 50 of which have occurred within the past 3 years. To date, 34 children have been born from mothers who have received a living donor uterine transplant.\n\nThis is a prospective study to treat Absolute Uterine Factor Infertility (AUFI) through uterine transplantation utilizing a uterus from a living or deceased donor resulting in live birth. A total of 10 biologically female (XX Karyotype) subjects will receive a uterine transplant.",[27,28,29],"Mayer Rokitansky Kuster Hauser Syndrome","Absence of Uterus","Infertility of Uterine Origin",[31,32,33,34,35],"Uterine Transplant","AUFI","Absolute Uterine Factor Infertility","Infertility","MRKH","RECRUITING","2026-04-24",{"date":39,"type":40},"2026-04-29","ACTUAL",{"date":42,"type":40},"2022-06-03",{"date":44,"type":21},"2030-12",{"name":46,"class":47},"John Goss","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100617681","clinical-and-imaging-features-in-mrkh-syndrome-100617681","NCT07321782","Clinical and Imaging Features in MRKH Syndrome","Mayer Rokitansky Kuster Hauser (MRKH) Syndrome: A Monocentric Ambispective Study on Clinical and Ultrasound Findings and Novel Imaging-Based Classification","ROK-US","Inclusion Criteria\n\n* Female patients with suspected or previously diagnosed MRKH syndrome\n* 46,XX karyotype\n* Age 10-60 years\n* For prospective patients: signed Informed Consent and Consent to Data Processing (by patient or parent\u002Fguardian if minor)\n* For retrospective patients: availability of data collected in compliance with Data Protection regulations (DPIA conducted)\n\nExclusion Criteria\n\n* Patients with other causes of primary amenorrhea (e.g., Androgen Insensitivity Syndrome \u002F Morris syndrome)\n* Karyotype different from 46,XX\n* For prospective patients: inability to provide informed consent or parental\u002Fguardian consent if minor","10 Years","60 Years",{"count":60,"type":21},25,"12 Months","OBSERVATIONAL","Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is a congenital condition characterized by uterovaginal agenesis in phenotypically normal women with a 46,XX karyotype. Despite increasing knowledge of its clinical and genetic features, MRKH syndrome shows marked phenotypic heterogeneity, and current classification systems do not fully reflect the wide spectrum of anatomical presentations encountered in clinical practice.\n\nThis ambispective, observational, monocenter study aims to describe the clinical, sonographic, radiological, and genetic characteristics of patients with suspected or confirmed MRKH syndrome referred to a tertiary referral center. All enrolled patients will undergo standardized pelvic ultrasound evaluation, including transabdominal and transrectal approaches, with optional MRI according to clinical indications. Sonovaginography will be performed to objectively assess vaginal length. Genetic investigations, including array CGH and next-generation sequencing, will be conducted as part of routine clinical care.\n\nThe primary objective is to characterize the clinical and ultrasound features of MRKH syndrome. Secondary objectives include the development of a novel image-based classification system to better describe disease severity and morphological patterns, validation of sonovaginography for vaginal length measurement, and correlation of genetic alterations with ultrasound-based staging. The study aims to improve diagnostic standardization and contribute to a better understanding of the genotype-phenotype relationship in MRKH syndrome.",[27,65],"Müllerian Agenesis","NOT_YET_RECRUITING","2025-12-22",{"date":69,"type":40},"2026-01-07",{"date":71,"type":21},"2026-01-12",{"date":73,"type":21},"2027-01-31",{"name":75,"class":47},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":16,"minAge":83,"maxAge":18,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":48},"100338697","feasibility-study-of-uterine-transplantation-from-living-donors-in-terms-of-efficacy-and-safety-in-patients-with-mayer-rokitansky-kster-hauser-syndrome-mrkh-100338697","NCT03689842","Feasibility Study of Uterine Transplantation From Living Donors in Terms of Efficacy and Safety in Patients With Mayer-Rokitansky-Küster-Hauser Syndrome (MRKH)","Inclusion Criteria:\n\nGraft recipient is a patient with Mayer-Rokitansky-Küster-Hauser Type I Uterine Vaginal Agenesis (without renal, cardiac and bone malformations):\n\n* Being aged between 18 and 38 years old\n* In stable couple, with a pregnancy project, favorable psychological evaluation\n* No history of cancer and transfusion\n\nThe living donor is a woman related to the Graft recipient with\n\n* Absence of comorbidity (neurological, nephro-urological pathology, infectious, psychiatric or psychological pathology)\n* Absence of uterine surgery, abdomino-pelvic major pathology history\n\nExclusion Criteria:\n\nGraft recipient:\n\n* Extreme oligo-astheno-spermia and azoospermia in the husband\n* History of abdominopelvic surgery excluding uncomplicated appendectomy; vaginal residue not allowing anastomosis\n\nLiving donor :\n\n* Known thromboembolic risk factor\n* No Compatibility with the recipient (group, rhesus, HLA)",true,"18 Years",{"count":85,"type":21},20,[24],"In France, one in 4500 women is affected by the MayerRokitantskyKüsterHauser (MRKH) syndrome which is characterized by the absence of uterus at birth. Currently, the only solutions for these patients are:\n\n* Gestational surrogacy, prohibited in France\n* Adoption\n* Resignation\n\nUterine transplantation could become a good alternative.\n\nThis study is conducted in 10 patients with MRKH type I syndrome, who will be transplanted from a living donor uterus",[27],"2025-03-04",{"date":91,"type":40},"2025-03-07",{"date":93,"type":40},"2017-12-14",{"date":95,"type":21},"2034-12-14",{"name":97,"class":47},"Hopital Foch",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":4},"100555135","neovaginoplasty-using-photoinduced-imine-crosslink-hydrogel-in-mrkh-patients-100555135","NCT06508151","Neovaginoplasty Using Photoinduced-imine-crosslink Hydrogel in MRKH Patients","Study on the Effectiveness and Safety of Neovaginoplasty Using Photoinduced-imine-crosslink Hydrogel in Patients With Mayer-Rokitansky-Kuster-Hauser Syndrome","Inclusion Criteria:\n\n1. Diagnosed with MRKH syndrome;\n2. Without previous related treatments; 3)18-35 years old;\n\n4)Voluntary agreement to participate in the study, sign the informed consent form, and demonstrate good compliance with follow-up.\n\nExclusion Criteria:\n\n1. With any previous artificial colpoplasty or other related treatment;\n2. With history of diabetes or systemic immune system disease.","35 Years",{"count":85,"type":21},[24],"Evaluating the effectiveness and safety of neovaginoplasty using photoinduced-imine-crosslink hydrogel in patients with MRKH syndrome by comparing the differences in the degree of squamous epithelialization, vaginal length and width, and sexual life quality.",[27],[111,112,113],"Photoinduced-imine-crosslink hydrogel","MRKH syndrome","Neovaginoplasty","2024-07-12",{"date":116,"type":40},"2024-07-18",{"date":118,"type":21},"2024-08-01",{"date":120,"type":21},"2026-06-30",{"name":122,"class":47},"Obstetrics & Gynecology Hospital of Fudan University",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":48},"100305177","uterus-transplantation-from-a-multi-organ-donor-100305177","NCT03252795","Uterus Transplantation From a Multi-organ Donor","Uterus Transplantation From a Multi-organ Donor: A Prospective Trial","Inclusion Criteria:\n\n* Female with Maier-Rokitansky-Kuster-Hauser syndrome\n* Mucosal neovagina of at least 7 cm\n* In a stable relationship for at least 1 year\n* Child wish\n* Good renal function (and presence of both kidneys)\n* Psychologically stable and compliant\n* At least 8 frozen embryos after IVF\u002Fintracytoplasmic sperm injection \\[ICSI\\]\n* Living in Belgium and a good health insurance\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Major pelvic surgery\n* Major chronic illnesses\n* Other risk factors or malignancies\n* BMI \\> 30","38 Years",{"count":85,"type":21},[24],"Uterus transplantation: screening, in vitro fertilization \\[IVF\\] treatment to be able to freeze embryos, uterus transplantation, pregnancy and afterwards removal of the uterus.",[135,27],"Infertility, Female",[137,27,138],"Infertility, female","Transplantation; Deceased donor","2024-02-13",{"date":141,"type":40},"2024-02-14",{"date":143,"type":40},"2016-11-03",{"date":145,"type":21},"2027-12-31",{"name":147,"class":47},"University Hospital, Ghent",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":35,"eligibilityCriteria":154,"healthyVolunteers":82,"sex":155,"minAge":4,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100283303","molecular-genetic-study-of-mayer-rokitansky-kuster-hauser-syndrome-100283303","NCT02967822","Molecular Genetic Study of Mayer-Rokitansky-Kuster-Hauser Syndrome","Etude de Génétique moléculaire du Syndrome de Mayer-Rokitansky-Kuster-Hauser","Inclusion Criteria:\n\n* Patient with MRKH syndrome OR healthy relative of patient included\n* Having signed the Informed consent form (or parents in case of patient under 18 years)\n\nExclusion Criteria:\n\n* Refusal to participate in genetic analyses\n* Participation in a therapeutical clinical study in the 30 days prior to inclusion in the present study.","ALL",{"count":157,"type":21},410,"In order to understand the molecular mechanisms leading to Mayer-Rokitansky-Kuster-Hauser syndrome (MRKH), the research team has to identify molecular bases of this anomaly.\n\nToward this goal, the research team would like to include in the study patients with MRKH syndrome, as well as their healthy relatives, in order to perform genetic analyses, especially whole exome sequencing.\n\nThis study has been set up in order to collect biological samples from patients with MRKH and their relatives.",[27],"2018-10-10",{"date":162,"type":40},"2018-10-12",{"date":164,"type":4},"2016-05",{"date":166,"type":21},"2031-05",{"name":168,"class":47},"Imagine Institute",2]